
Enovis Corp (ENOV) Stock Forecast & Price Target
Enovis Corp (ENOV) Analyst Ratings
Bulls say
Enovis is a medical technology company with a compelling product portfolio and strong market positioning, which is reflected in its solid financial results and steady growth in the Prevention & Recovery segment. Despite potential risks, such as slower-than-expected top-line growth and tariff pressures, the company's significant investments in new product development and M&A integration are expected to drive further growth and margin expansion. As a result, the company's current valuation is perceived as too low and we see potential for multiple expansion as Enovis continues to deliver above market growth.
Bears say
Enovis is facing multiple headwinds, including softer Western Europe volumes, Middle East conflict, and higher inflationary headwinds, resulting in a projected decline in revenue growth for the fiscal year 2026. The company also has a high debt level and is reliant on cross-selling opportunities and new product launches for future growth, which may not materialize. Additionally, competition in key segments of the company's end-markets and potential tariff exposure also pose risks that could impact the company's financial performance. Overall, these factors contribute to a negative outlook on Enovis's stock.
This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.
Enovis Corp (ENOV) Analyst Forecast & Price Prediction
Start investing in Enovis Corp (ENOV)
Order type
Buy in
Order amount
Est. shares
0 shares